Cargando…
Dual-release hydrocortisone treatment: glycometabolic profile and health-related quality of life
OBJECTIVE: Adrenal insufficiency (AI) is a chronic condition associated with increased mortality and morbidity. The treatment of AI in the last years has been object of important changes due to the development of a dual-release preparation of hydrocortisone. It differs from previous therapeutic stra...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5793805/ https://www.ncbi.nlm.nih.gov/pubmed/29233815 http://dx.doi.org/10.1530/EC-17-0368 |
_version_ | 1783297024629669888 |
---|---|
author | Mongioì, L M Condorelli, R A La Vignera, S Calogero, A E |
author_facet | Mongioì, L M Condorelli, R A La Vignera, S Calogero, A E |
author_sort | Mongioì, L M |
collection | PubMed |
description | OBJECTIVE: Adrenal insufficiency (AI) is a chronic condition associated with increased mortality and morbidity. The treatment of AI in the last years has been object of important changes due to the development of a dual-release preparation of hydrocortisone. It differs from previous therapeutic strategy as it contemplates a once-daily tablet that allows more closely mimicking the physiological circadian cortisol rhythm. The aim of the study was to evaluate the effects of dual-release hydrocortisone treatment on the glycometabolic profile and health-related quality of life of patients with AI. DESIGN AND METHODS: In this clinical open trial, we enrolled ten patients with primary AI (41 ± 2.67 years) and nine patients with AI secondary to hypopituitarism (53.2 ± 17.7 years). We evaluated the glycometabolic profile before and 3, 6, 9 and 12 months after dual-release hydrocortisone administration. We also evaluated health-related quality of life, estimated by the AddiQol questionnaire. The mean dose administered of dual-release hydrocortisone was 28.33 ± 6.68 mg/day. RESULTS: One female hypopituitary patient dropped out from the study. After 12 months of treatment, the mean dosage administered of dual-release hydrocortisone was significantly lower (P < 0.05) and all patients reported improved quality of life and well-being. The glycometabolic profile improved and the glycosylated hemoglobin decreased significantly in patients with primary AI (6.25 ± 0.2 vs 5.35 ± 0.17, P < 0.05). In contrast, hypopituitary patients had worse glycometabolic profile and a trend toward hypertriglyceridemia. CONCLUSIONS: Dual-release hydrocortisone treatment improved the quality of life of patients with AI, and it allowed a decrease of cortisol dosage administered in the absence of side effects. The glycometabolic profile worsened in hypopituitary patients. |
format | Online Article Text |
id | pubmed-5793805 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Bioscientifica Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-57938052018-02-06 Dual-release hydrocortisone treatment: glycometabolic profile and health-related quality of life Mongioì, L M Condorelli, R A La Vignera, S Calogero, A E Endocr Connect Research OBJECTIVE: Adrenal insufficiency (AI) is a chronic condition associated with increased mortality and morbidity. The treatment of AI in the last years has been object of important changes due to the development of a dual-release preparation of hydrocortisone. It differs from previous therapeutic strategy as it contemplates a once-daily tablet that allows more closely mimicking the physiological circadian cortisol rhythm. The aim of the study was to evaluate the effects of dual-release hydrocortisone treatment on the glycometabolic profile and health-related quality of life of patients with AI. DESIGN AND METHODS: In this clinical open trial, we enrolled ten patients with primary AI (41 ± 2.67 years) and nine patients with AI secondary to hypopituitarism (53.2 ± 17.7 years). We evaluated the glycometabolic profile before and 3, 6, 9 and 12 months after dual-release hydrocortisone administration. We also evaluated health-related quality of life, estimated by the AddiQol questionnaire. The mean dose administered of dual-release hydrocortisone was 28.33 ± 6.68 mg/day. RESULTS: One female hypopituitary patient dropped out from the study. After 12 months of treatment, the mean dosage administered of dual-release hydrocortisone was significantly lower (P < 0.05) and all patients reported improved quality of life and well-being. The glycometabolic profile improved and the glycosylated hemoglobin decreased significantly in patients with primary AI (6.25 ± 0.2 vs 5.35 ± 0.17, P < 0.05). In contrast, hypopituitary patients had worse glycometabolic profile and a trend toward hypertriglyceridemia. CONCLUSIONS: Dual-release hydrocortisone treatment improved the quality of life of patients with AI, and it allowed a decrease of cortisol dosage administered in the absence of side effects. The glycometabolic profile worsened in hypopituitary patients. Bioscientifica Ltd 2017-12-12 /pmc/articles/PMC5793805/ /pubmed/29233815 http://dx.doi.org/10.1530/EC-17-0368 Text en © 2018 The authors http://creativecommons.org/licenses/by-nc/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Research Mongioì, L M Condorelli, R A La Vignera, S Calogero, A E Dual-release hydrocortisone treatment: glycometabolic profile and health-related quality of life |
title | Dual-release hydrocortisone treatment: glycometabolic profile and health-related quality of life |
title_full | Dual-release hydrocortisone treatment: glycometabolic profile and health-related quality of life |
title_fullStr | Dual-release hydrocortisone treatment: glycometabolic profile and health-related quality of life |
title_full_unstemmed | Dual-release hydrocortisone treatment: glycometabolic profile and health-related quality of life |
title_short | Dual-release hydrocortisone treatment: glycometabolic profile and health-related quality of life |
title_sort | dual-release hydrocortisone treatment: glycometabolic profile and health-related quality of life |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5793805/ https://www.ncbi.nlm.nih.gov/pubmed/29233815 http://dx.doi.org/10.1530/EC-17-0368 |
work_keys_str_mv | AT mongioilm dualreleasehydrocortisonetreatmentglycometabolicprofileandhealthrelatedqualityoflife AT condorellira dualreleasehydrocortisonetreatmentglycometabolicprofileandhealthrelatedqualityoflife AT lavigneras dualreleasehydrocortisonetreatmentglycometabolicprofileandhealthrelatedqualityoflife AT calogeroae dualreleasehydrocortisonetreatmentglycometabolicprofileandhealthrelatedqualityoflife |